ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.060
-0.010 (-0.48%)
At close: Jul 1, 2026, 4:00 PM EDT
2.087
+0.027 (1.33%)
After-hours: Jul 1, 2026, 4:16 PM EDT
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
277.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 157.08M |
| Niagen Bioscience | 130.42M |
| Invivyd | 55.87M |
| Orchestra BioMed Holdings | 32.72M |
| ProQR Therapeutics | 15.73M |
| Whitehawk Therapeutics | 7.15M |
| Entrada Therapeutics | 5.74M |
ALXO News
- 1 day ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 1 day ago - ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds - TheFly
- 1 day ago - ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - GlobeNewsWire
- 21 days ago - ALX Oncology Holdings Transcript: AGM 2026 - Transcripts
- 27 days ago - ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York - GlobeNewsWire
- 7 weeks ago - ALX Oncology Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - ALX Oncology Holdings Earnings release: Q1 2026 - Filings